AQR Capital Management LLC bought a new stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 202,241 shares of the biotechnology company's stock, valued at approximately $1,155,000. AQR Capital Management LLC owned approximately 0.14% of Aurinia Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently bought and sold shares of the stock. PFG Investments LLC grew its stake in Aurinia Pharmaceuticals by 37.9% during the second quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company's stock valued at $164,000 after acquiring an additional 7,900 shares in the last quarter. Rhumbline Advisers grew its stake in Aurinia Pharmaceuticals by 13.3% during the second quarter. Rhumbline Advisers now owns 208,263 shares of the biotechnology company's stock valued at $1,189,000 after acquiring an additional 24,371 shares in the last quarter. Banque Cantonale Vaudoise grew its stake in Aurinia Pharmaceuticals by 126.6% during the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 5,410 shares in the last quarter. HighMark Wealth Management LLC grew its stake in Aurinia Pharmaceuticals by 21.3% during the second quarter. HighMark Wealth Management LLC now owns 91,196 shares of the biotechnology company's stock valued at $521,000 after acquiring an additional 16,000 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Aurinia Pharmaceuticals by 18.8% during the second quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company's stock valued at $2,791,000 after acquiring an additional 77,510 shares in the last quarter. 36.83% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Aurinia Pharmaceuticals
In other news, insider Scott Michael Habig sold 18,249 shares of the firm's stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total value of $96,902.19. Following the completion of the sale, the insider now owns 456,338 shares in the company, valued at approximately $2,423,154.78. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.30% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have commented on AUPH. HC Wainwright reissued a "buy" rating and issued a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. Cantor Fitzgerald reissued an "overweight" rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Aurinia Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $10.00.
Check Out Our Latest Report on AUPH
Aurinia Pharmaceuticals Price Performance
Shares of NASDAQ:AUPH traded up $0.10 on Friday, reaching $7.08. The company's stock had a trading volume of 895,175 shares, compared to its average volume of 1,658,434. The company has a 50-day simple moving average of $6.64 and a 200 day simple moving average of $5.80. The company has a market cap of $1.01 billion, a P/E ratio of -16.47 and a beta of 1.44. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.82 and a current ratio of 5.33. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.71 and a 52-week high of $10.05.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The firm had revenue of $57.10 million during the quarter, compared to analyst estimates of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. The business's revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.08) EPS. As a group, equities research analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.13 EPS for the current fiscal year.
About Aurinia Pharmaceuticals
(
Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Stories
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
